Occam Places Allison August as CMO at Comanche Bio
Comanche Biopharma is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has appointed Allison August, M.D. as Chief Medical Officer. Dr. August, an obstetrician-gynecologist, brings more than 25 years of clinical experience to her position at Comanche Biopharma.
August joins Comanche Biopharma from Moderna, where she was Vice President of Clinical Development, Infectious Diseases, and spent over five years in various roles with increasing responsibility for the development of mRNA-based vaccines and the first mRNA-encoded monoclonal antibody.
Before moving to the biopharma industry, August was an academic and private practice obstetrician-gynecologist. Her academic career included faculty positions at the Brown University Medical School and adjunct faculty at Harvard Medical School affiliated hospitals. Dr. August holds a B.A. in the History of Religion from Bryn Mawr College and an M.D. from the University of Chicago
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.